<DOC>
	<DOCNO>NCT02493998</DOCNO>
	<brief_summary>Mucopolysaccharidosis type IIIB ( MPS IIIB , also know Sanfilippo Syndrome Type B ) severe neurodegenerative disorder . The purpose study learn health problem patient MPS IIIB measure problem time . It particularly look disease develop young child . This observational study , experimental drug give . The result study help u design future study measure whether health problem get well give experimental drug MPS IIIB .</brief_summary>
	<brief_title>A Study Mucopolysaccharidosis Type IIIB ( MPS IIIB )</brief_title>
	<detailed_description>This multicenter , multinational , longitudinal , observational study subject 1 10 year age diagnose MPS IIIB . Data prospectively collect 20 30 subject understand clinical progression MPS IIIB term neurocognitive function , behavior , quality life , image characteristic , genotype , biochemical marker disease burden . This information may help inform design interpretation subsequent interventional study .</detailed_description>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>Individuals eligible participate study must meet following criterion : Has deficient NAGLU enzyme activity Screening . Blood NAGLU enzyme activity collect analyze centrally . Is ≥ 1 ≤ 10 year age ageequivalent ≥ 12 month VABSII DQ ≥ 50 ( determine BSIDIII KABCII ) Has present signs/symptoms consistent MPS IIIB ; individual present signs/symptoms disease ( e.g. , sibling know patient ) , determination eligibility discretion BioMarin medical monitor conjunction site investigator . Written inform consent parent legal guardian assent subject , require Has ability comply protocol requirement , opinion investigator Has another neurological illness may cause cognitive decline ( e.g. , trauma , meningitis , hemorrhage ) study entry Requires ventilation support , except noninvasive support night Has receive stem cell , gene therapy ERT MPS IIIB Has contraindication neurosurgery ( e.g. , congenital heart disease , severe respiratory impairment , clot abnormality ) Has contraindication MRI scan ( e.g. , cardiac pacemaker , metal fragment chip eye , aneurysm clip brain ) Has history poorly control seizure disorder Is prone complication intraventricular drug administration , include patient hydrocephalus ventricular shunt Has receive investigational medication within 30 day prior Baseline visit schedule receive investigational drug course study Has medical condition extenuate circumstance , opinion investigator , might compromise subject 's ability comply protocol requirement , subject 's wellbeing safety , interpretability subject 's clinical data .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Sanfilippo Syndrome Type B</keyword>
</DOC>